CA2731171C - Pkc-activating compounds for the treatment of neurodegenerative diseases - Google Patents

Pkc-activating compounds for the treatment of neurodegenerative diseases Download PDF

Info

Publication number
CA2731171C
CA2731171C CA2731171A CA2731171A CA2731171C CA 2731171 C CA2731171 C CA 2731171C CA 2731171 A CA2731171 A CA 2731171A CA 2731171 A CA2731171 A CA 2731171A CA 2731171 C CA2731171 C CA 2731171C
Authority
CA
Canada
Prior art keywords
acid
pkc
methyl ester
ester
cyclopropanated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2731171A
Other languages
English (en)
French (fr)
Other versions
CA2731171A1 (en
Inventor
Thomas J. Nelson
Daniel L. Alkon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
West Virginia University
Original Assignee
Blanchette Rockefeller Neuroscience Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blanchette Rockefeller Neuroscience Institute filed Critical Blanchette Rockefeller Neuroscience Institute
Priority to CA2941035A priority Critical patent/CA2941035A1/en
Publication of CA2731171A1 publication Critical patent/CA2731171A1/en
Application granted granted Critical
Publication of CA2731171C publication Critical patent/CA2731171C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C07D303/42—Acyclic compounds having a chain of seven or more carbon atoms, e.g. epoxidised fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/13—Monohydroxylic alcohols containing saturated rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/13—Monohydroxylic alcohols containing saturated rings
    • C07C31/133—Monohydroxylic alcohols containing saturated rings monocyclic
    • C07C31/1333—Monohydroxylic alcohols containing saturated rings monocyclic with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/608—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a ring other than a six-membered aromatic ring in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
CA2731171A 2008-07-28 2009-07-28 Pkc-activating compounds for the treatment of neurodegenerative diseases Expired - Fee Related CA2731171C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2941035A CA2941035A1 (en) 2008-07-28 2009-07-28 Pkc-activating compounds for the treatment of neurodegenerative diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8417208P 2008-07-28 2008-07-28
US61/084,172 2008-07-28
PCT/US2009/051927 WO2010014585A1 (en) 2008-07-28 2009-07-28 Pkc-activating compounds for the treatment of neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2941035A Division CA2941035A1 (en) 2008-07-28 2009-07-28 Pkc-activating compounds for the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
CA2731171A1 CA2731171A1 (en) 2010-02-04
CA2731171C true CA2731171C (en) 2016-10-18

Family

ID=41136734

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2941035A Abandoned CA2941035A1 (en) 2008-07-28 2009-07-28 Pkc-activating compounds for the treatment of neurodegenerative diseases
CA2731171A Expired - Fee Related CA2731171C (en) 2008-07-28 2009-07-28 Pkc-activating compounds for the treatment of neurodegenerative diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2941035A Abandoned CA2941035A1 (en) 2008-07-28 2009-07-28 Pkc-activating compounds for the treatment of neurodegenerative diseases

Country Status (6)

Country Link
US (7) US8163800B2 (enExample)
EP (3) EP2328572B1 (enExample)
JP (4) JP5653917B2 (enExample)
CA (2) CA2941035A1 (enExample)
ES (1) ES2683021T3 (enExample)
WO (1) WO2010014585A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090030055A1 (en) * 2002-07-02 2009-01-29 Thomas Nelson PKC activation as a means for enhancing sAPPALPHA secretion and improving cognition using bryostatin type compounds
US8163800B2 (en) * 2008-07-28 2012-04-24 Blanchette Rockefeller Neurosciences Institute PKC-activating compounds for the treatment of neurodegenerative diseases
JP5934102B2 (ja) 2009-10-30 2016-06-15 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ誘導体による酸化ストレス障害の緩和
ES2538208T3 (es) * 2010-02-22 2015-06-18 Blanchette Rockefeller Neurosciences Institute Alteraciones específicas de la enfermedad de Alzheimer de los niveles de proteína quinasa C épsilon (PKC-épsilon)
US9107890B2 (en) * 2010-07-08 2015-08-18 Blanchette Rockefeller Neurosciences Institute PKC activators and anticoagulant in regimen for treating stroke
EP2605773A1 (en) 2010-08-19 2013-06-26 Blanchette Rockefeller Neurosciences, Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
CA2834342C (en) * 2011-04-26 2021-08-31 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
AU2012249921B2 (en) 2011-04-26 2017-06-08 Biojiva Llc Oxidative retinal diseases
KR102110175B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 Ｐｕｆａ 산화와 관련된 장애
WO2012148926A2 (en) * 2011-04-26 2012-11-01 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating pufas
EP2764120B1 (en) 2011-10-05 2020-06-10 Blanchette Rockefeller Neurosciences, Institute Stimulus-elicited genomic profile markers of a neurodegenerative condition
CA2855932A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
CA2856235A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Esters of dcpla for the treatment of neurodegenerative disorders
EP2957285B1 (en) 2013-02-15 2018-01-10 Nishizaki Bioinformation Research Institute Phospholipid compound containing unsaturated fatty acid derivative having cyclopropane ring
US20160025704A1 (en) * 2013-03-15 2016-01-28 Daniel L. Alkon Methods for identifying neuroprotective pkc activators
ES2927760T3 (es) * 2013-10-18 2022-11-10 Blanchette Rockefeller Neurosciences Inst Esteres halogenados de ácidos grasos insaturados ciclopropanados para su utilización en el tratamiento de las enfermedades neurodegenerativas
WO2015160851A1 (en) 2014-04-18 2015-10-22 Neurotrope Bioscience Methods and compositions for treatment of lipid storage disorders
US9413754B2 (en) 2014-12-23 2016-08-09 Airwatch Llc Authenticator device facilitating file security
EP3294290A1 (en) 2015-05-11 2018-03-21 Alkon, Daniel, L. Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
US20180256537A1 (en) 2015-09-23 2018-09-13 Tapan K. Khan Methods for survival and rejuvenation of dermal fibroblasts using pkc activators
WO2017062924A1 (en) 2015-10-08 2017-04-13 Alkon Daniel L Dosing regimens of pkc activators
EP3380452B1 (en) 2015-11-23 2021-03-24 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
JP6912072B2 (ja) * 2016-12-14 2021-07-28 国立大学法人山口大学 前頭側頭型認知症の予防又は治療用医薬
WO2018187647A1 (en) 2017-04-06 2018-10-11 Neurotrope Bioscience, Inc. Methods and compositions for treatment of neurological diseases, disorders, or conditions
US20190350898A1 (en) * 2018-05-18 2019-11-21 Neurotrope Bioscience, Inc. Methods and compositions for treatment of alzheimer's disease
WO2020118282A1 (en) * 2018-12-07 2020-06-11 The Johns Hopkins University Methods, compositions and kits for treating multiple sclerosis and other disorders
US11779910B2 (en) 2020-02-21 2023-10-10 Biojiva Llc Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
US20220133687A1 (en) * 2020-11-02 2022-05-05 Synaptogenix, Inc. Methods of treating and preventing neurodegenerative diseases with hgf activating compounds
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US20240180869A1 (en) * 2021-02-08 2024-06-06 Synaptogenix, Inc. Treatment of multiple sclerosis using pkc activators
US20240165075A1 (en) * 2021-02-08 2024-05-23 Synaptogenix, Inc. Treatment of optic nerve inflammation using pkc activators
WO2023225073A1 (en) * 2022-05-18 2023-11-23 Virginia Commonwealth University Methods for treatment of cognitive impairment in cirrhosis patients
WO2025056602A1 (en) 2023-09-11 2025-03-20 Elastin Biosciences Ltd. Pharmaceutical compositions and use thereof in treatment of conditions and diseases related to elastin deficiency and/or aging

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080784A (en) 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US5242932A (en) 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
DK0618968T3 (da) 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
JPH06279311A (ja) 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼｃアイソザイムの活性化剤
US6107050A (en) 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US5976816A (en) 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US20030108956A1 (en) 1993-05-03 2003-06-12 Alkon Daniel L. Cell tests for Alzheimer's disease
US7625697B2 (en) 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5863902A (en) 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6001580A (en) 1995-03-28 1999-12-14 Takeda Chemical Industries, Inc. Method for assaying ERK2 map kinase
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
AU2316797A (en) 1996-02-29 1997-09-16 Mount Sinai Hospital Corporation Shc proteins
JPH1090263A (ja) 1996-07-25 1998-04-10 Mclean Hospital Corp:The アルツハイマー病の診断のためのｅｒｋ−１およびｅｒｋ−２の利用
JP2002526775A (ja) 1998-10-01 2002-08-20 テイテイエブスキ，アレクセイ・ウラデイミロビチ ＧＤＮＦについての新規Ｒｅｔ非依存性シグナリング経路
WO2000070099A2 (en) 1999-05-19 2000-11-23 Mitokor Differential gene expression in specific regions of the brain in neurodegenerative diseases
EP1224463A2 (en) 1999-10-08 2002-07-24 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
CA2401270A1 (en) 2000-03-10 2001-09-20 Jeff W. Lichtman Method for labeling individual cells
JP2003528071A (ja) 2000-03-23 2003-09-24 エラン ファーマスーティカルズ インコーポレイテッド アルツハイマー病治療用組成物および方法
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
BR0110051A (pt) 2000-04-03 2004-12-07 Bristol Myers Squibb Pharma Co Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer
AU2001257006A1 (en) 2000-04-11 2001-10-23 Du Pont Pharmaceuticals Company Substituted lactams as inhibitors of abeta protein production
ATE302751T1 (de) 2000-06-30 2005-09-15 Elan Pharm Inc Verbindungen zur behandlung der alzheimerischen krankheit
US6803233B2 (en) 2000-07-31 2004-10-12 The Regents Of The University Of California Model for Alzheimer's disease and other neurodegenerative diseases
ES2267853T3 (es) 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
AUPR215700A0 (en) * 2000-12-19 2001-01-25 Fujisawa Pharmaceutical Co., Ltd. Carboxylic acid compound having cyclopropane ring
US7374911B2 (en) 2000-12-21 2008-05-20 Labow Mark A Interleukin-1 related gene and protein
EP1358329A2 (en) 2001-02-06 2003-11-05 Incyte Genomics, Inc. Lipid-associated molecules
AU2002254029A1 (en) 2001-02-27 2002-09-12 Daniel L. Alkon Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
JP4024554B2 (ja) 2001-02-27 2007-12-19 松下電器産業株式会社 燃料電池発電システム
US6874208B2 (en) 2001-03-14 2005-04-05 Autoliv Asp, Inc. Anchoring attachment apparatus
MXPA04000140A (es) 2001-06-27 2004-06-03 Elan Pharm Inc Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer.
US20040014678A1 (en) 2001-08-08 2004-01-22 Antonella Favit Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway
WO2004083241A2 (en) 2003-03-19 2004-09-30 Takeda Pharmaceutical Company Limited Btc-interacting proteins and use thereof
US7595159B2 (en) 2004-11-03 2009-09-29 The Brigham And Women's Hospital, Inc. Prediction of Parkinson's disease using gene expression levels of peripheral blood samples
WO2006054979A1 (en) 2004-11-15 2006-05-26 Blanchette Rockefeller Neurosciences Institute Abnormalities of phosphatase 2a (pp2a) for diagnosis and treatment of alzheimer’s disease
US20090182021A1 (en) 2005-08-03 2009-07-16 Nanternet Philippe G Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
WO2007047029A2 (en) 2005-10-11 2007-04-26 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
WO2007043998A1 (en) 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio
WO2007044094A1 (en) 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
WO2007149985A2 (en) 2006-06-21 2007-12-27 Lexicor Medical Technology, Llc Assessing dementia and dementia-type disorders
JP2008143819A (ja) * 2006-12-08 2008-06-26 Tomoyuki Nishizaki 酸化ストレス誘導細胞死の抑制剤
EP3332797A3 (en) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
US20100209914A1 (en) 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
AU2009310374B2 (en) * 2008-03-03 2014-06-19 Rxbio, Inc. LPA receptor agonists and antagonists
US8163800B2 (en) 2008-07-28 2012-04-24 Blanchette Rockefeller Neurosciences Institute PKC-activating compounds for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
WO2010014585A1 (en) 2010-02-04
JP5653917B2 (ja) 2015-01-14
JP2015042643A (ja) 2015-03-05
JP2016172727A (ja) 2016-09-29
US10696644B2 (en) 2020-06-30
US9119825B2 (en) 2015-09-01
CA2731171A1 (en) 2010-02-04
EP3403650A3 (en) 2019-02-13
US20120149768A1 (en) 2012-06-14
US11820745B2 (en) 2023-11-21
EP3403650A2 (en) 2018-11-21
US20220356161A1 (en) 2022-11-10
EP2328572A1 (en) 2011-06-08
JP2018168170A (ja) 2018-11-01
US20100022645A1 (en) 2010-01-28
US20160060236A1 (en) 2016-03-03
US20200331875A1 (en) 2020-10-22
ES2683021T3 (es) 2018-09-24
EP2328572B1 (en) 2018-06-13
JP2011529503A (ja) 2011-12-08
US20240025870A1 (en) 2024-01-25
JP6449186B2 (ja) 2019-01-09
US10323011B2 (en) 2019-06-18
CA2941035A1 (en) 2010-02-04
EP3586839A1 (en) 2020-01-01
US11390596B2 (en) 2022-07-19
US8163800B2 (en) 2012-04-24
US20190270715A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
US11820745B2 (en) PKC-activating compounds for the treatment of neurodegenerative diseases
JP6446625B2 (ja) 脳卒中の治療法におけるｐｋｃ活性化因子および抗凝血剤
US20230235378A1 (en) Lzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon protein levels
US20240390324A1 (en) Methods of treating and preventing neurodegenerative diseases with hgf activating compounds
JP2024523589A (ja) アンジオテンシン及びその類似体の投与によるシナプス形成の誘導方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140702

MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831